Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments
Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technol...
Saved in:
Published in | Mass spectrometry reviews Vol. 28; no. 5; pp. 703 - 724 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.09.2009
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technologies and mass spectrometry (MS). In this review, we examine the limitations of proteomics, and aim towards the definition of the current key prerequisites. We focus on capillary electrophoresis coupled to mass spectrometry (CE-MS), because this technique continues to show great promise. We discuss CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. Finally, we present several examples on the use of CE-MS to determine urinary biomarkers and implications for disease diagnosis, prognosis, and therapy evaluation. |
---|---|
Bibliography: | http://dx.doi.org/10.1002/mas.20205 British Heart Foundation Chair and Programme - No. BHF/RG/07/005/23633 EUROTRANS-BIO - No. ETB-2006-016 Inserm "Direction Régional Clinique" (CHU de Toulouse, France) ArticleID:MAS20205 InGenious HyperCare - No. LSHM-C7-2006-037093 University of Wisconsin-Madison Beckman Foundation Statement of Competing Financial Interest: HM is the founder and co-owner of Mosaiques Diagnostics, which developed the CE-MS technology for clinical application. Wellcome Trust Cardiovascular Functional Genomics Initiative - No. 066780/2/012 "Deutsche-Jose-Carreras-Leukämie Stiftung" - No. DJCLS 98/05 "Deutsche Forschungsgemeinschaft" - No. DFG Mi-658/01 NIH - No. 1R01GM080148; No. DK078244; No. DK080301; No. DK071802; No. DK061525; No. DK064400 Thermo Fisher istex:AAA7563779A71467CF99AB9728F18F79E2D9C3A0 ark:/67375/WNG-5RPP5DC7-S Fondation pour la Recherche Médicale EURATools - No. LSHG-CT-2005-019015 ANR - No. ANR-07-PHYSIO-004-01 PREDICTIONS - No. 1272568 Statement of Competing Financial Interest: HM is the founder and co‐owner of Mosaiques Diagnostics, which developed the CE–MS technology for clinical application. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 |
ISSN: | 0277-7037 1098-2787 |
DOI: | 10.1002/mas.20205 |